


PHARMACEUTICAL 2022



CNBX Pharmaceuticals Inc. Rank 354 of 466





PHARMACEUTICAL 2022



CNBX Pharmaceuticals Inc. Rank 354 of 466

The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 44% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 16%, being 62% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	1,591
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,273
Liabilities, Non-Current	0
Other Assets	845
Other Compr. Net Income	869
Other Expenses	20
Other Liabilities	0
Other Net Income	-594
Other Revenues	0
Property and Equipment	643
Research and Development	1,772
Selling, General and Administrative Expense	808

Output Variable	Value in 1000 USD
Assets	3,079
Liabilities	1,273
Expenses	2,600
Revenues	0
Stockholders Equity	1,806
Net Income	-3,194
Comprehensive Net Income	-2,760
Economic Capital Ratio	16%

